Literature DB >> 2568677

Coagulopathy in hemorrhagic fever with renal syndrome (Korean hemorrhagic fever).

M Lee1, B K Kim, S Kim, S Park, J S Han, S T Kim, J S Lee.   

Abstract

The pathophysiology of bleeding manifestations in hemorrhagic fever with renal syndrome (HFRS) was elucidated by serially evaluating coagulation and fibrinolytic profiles and complement alterations in patients with HFRS. In the early stage of the disease, platelet counts, platelet survival time, and platelet aggregation in vitro decreased. Prolongation of bleeding time, prothrombin time, and activated partial thromboplastin time was noted, with decreases in coagulation factors II, V, VIII, IX, and X. Levels of fibrinogen were decreased, and those of fibrinogen-fibrin degradation products in serum and urine were increased. Concentrations of plasminogen, alpha 2-plasmin inhibitor, and antithrombin III in plasma were depressed. Procoagulant activity was present in plasma. Circulating immune complexes were found, whereas serum levels of C3 were decreased. In the early stage of HFRS, thrombocytopenia, defects in platelet function, and disseminated intravascular coagulation may play central roles in the pathogenesis of bleeding manifestations. Vasculopathy and immunologic aberrations also may play a role.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2568677

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  8 in total

1.  Pathogenesis of emerging severe fever with thrombocytopenia syndrome virus in C57/BL6 mouse model.

Authors:  Cong Jin; Mifang Liang; Junyu Ning; Wen Gu; Hong Jiang; Wei Wu; Fushun Zhang; Chuan Li; Quanfu Zhang; Hua Zhu; Ting Chen; Ying Han; Weilun Zhang; Shuo Zhang; Qin Wang; Lina Sun; Qinzhi Liu; Jiandong Li; Tao Wang; Qiang Wei; Shiwen Wang; Ying Deng; Chuan Qin; Dexin Li
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-04       Impact factor: 11.205

2.  Renal artery embolization of perirenal hematoma in hemorrhagic fever with renal syndrome: a case report.

Authors:  Hee Seok Choi; Yong Seok Lee; Jae Cheol Hwang; Ji Hyon Lim; Kyung Soo Kim; Yup Yoon
Journal:  Korean J Radiol       Date:  2007 Jul-Aug       Impact factor: 3.500

3.  Hantavirus pulmonary syndrome. Pathogenesis of an emerging infectious disease.

Authors:  S R Zaki; P W Greer; L M Coffield; C S Goldsmith; K B Nolte; K Foucar; R M Feddersen; R E Zumwalt; G L Miller; A S Khan
Journal:  Am J Pathol       Date:  1995-03       Impact factor: 4.307

4.  Haemostatic abnormalities in African swine fever a comparison of two virus strains of different virulence (Dominican Republic '78 and Malta '78).

Authors:  C J Villeda; S M Williams; P J Wilkinson; E Viñuela
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

5.  The fundamental role of endothelial cells in hantavirus pathogenesis.

Authors:  Jussi Hepojoki; Antti Vaheri; Tomas Strandin
Journal:  Front Microbiol       Date:  2014-12-22       Impact factor: 5.640

6.  Hantavirus Infection Suppresses Thrombospondin-1 Expression in Cultured Endothelial Cells in a Strain-Specific Manner.

Authors:  Svetlana F Khaiboullina; Sergey P Morzunov; Stephen C St Jeor; Albert A Rizvanov; Vincent C Lombardi
Journal:  Front Microbiol       Date:  2016-07-19       Impact factor: 5.640

7.  The intracellular cargo receptor ERGIC-53 is required for the production of infectious arenavirus, coronavirus, and filovirus particles.

Authors:  Joseph P Klaus; Philip Eisenhauer; Joanne Russo; Anne B Mason; Danh Do; Benjamin King; Douglas Taatjes; Cromwell Cornillez-Ty; Jonathan E Boyson; Markus Thali; Chunlei Zheng; Lujian Liao; John R Yates; Bin Zhang; Bryan A Ballif; Jason W Botten
Journal:  Cell Host Microbe       Date:  2013-11-13       Impact factor: 21.023

8.  β2 integrin mediates hantavirus-induced release of neutrophil extracellular traps.

Authors:  Martin J Raftery; Pritesh Lalwani; Ellen Krautkrӓmer; Thorsten Peters; Karin Scharffetter-Kochanek; Renate Krüger; Jörg Hofmann; Karl Seeger; Detlev H Krüger; Günther Schönrich
Journal:  J Exp Med       Date:  2014-06-02       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.